Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-12
DOI
10.1002/cncr.32582
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
- (2019) Archana R. Simmons et al. Cancer Prevention Research
- The role of biomarkers in the management of epithelial ovarian cancer
- (2017) Wei-Lei Yang et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection
- (2017) Renée Turzanski Fortner et al. GYNECOLOGIC ONCOLOGY
- Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients
- (2016) P. Zaenker et al. AUTOIMMUNITY REVIEWS
- A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
- (2016) K. L. Terry et al. CLINICAL CANCER RESEARCH
- CA125 and HE4: Measurement Tools for Ovarian Cancer
- (2016) Tingting Zhao et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2016) Ian J Jacobs et al. LANCET
- Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer
- (2016) Khalid El Bairi et al. CELLULAR ONCOLOGY
- Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis
- (2015) Jian-Xiang Shi et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening
- (2015) Usha Menon et al. JOURNAL OF CLINICAL ONCOLOGY
- A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value
- (2013) Karen H. Lu et al. CANCER
- Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
- (2013) Elham O Hamed et al. Diagnostic Pathology
- Anti-HE4 antibodies in infertile women and women with ovarian cancer
- (2013) Ingegerd Hellstrom et al. GYNECOLOGIC ONCOLOGY
- HE4 combined with CA125: favorable screening tool for ovarian cancer
- (2013) Nasrin Ghasemi et al. MEDICAL ONCOLOGY
- Ovarian Cancer Screening
- (2012) Steven J. Skates INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
- (2011) T Van Gorp et al. BRITISH JOURNAL OF CANCER
- Development of an ovarian cancer screening decision model that incorporates disease heterogeneity
- (2010) Laura J. Havrilesky et al. CANCER
- CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations
- (2010) D. W. Cramer et al. CLINICAL CHEMISTRY
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
- (2008) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
- (2007) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started